A 72-year-old man with diabetes mellitus type 2 is admitted to the ICU post-operatively (day 5 after abdominal surgery) with fever (39.2°C), purulent endotracheal secretions, and a new infiltrate on chest X-ray. He has been on mechanical ventilation for 3 days. Sputum culture grows *Pseudomonas aeruginosa* resistant to fluoroquinolones. Blood glucose is 280 mg/dL. What is the most appropriate initial antibiotic regimen?

Explanation

## Clinical Diagnosis: Ventilator-Associated Pneumonia (VAP) **Key Point:** This patient has **VAP** (ventilator-associated pneumonia), not CAP. The defining features are: - Mechanical ventilation for ≥48 hours - New pulmonary infiltrate post-operatively - Positive sputum culture for *Pseudomonas aeruginosa* - Post-operative day 5 (late-onset VAP, >5 days) **High-Yield:** Late-onset VAP (>5 days) is caused by multidrug-resistant (MDR) gram-negative organisms, particularly *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. Fluoroquinolone resistance is common in VAP pathogens. ## Antibiotic Selection for VAP with *Pseudomonas* | Antibiotic Class | Efficacy in VAP | Notes | | --- | --- | --- | | **Piperacillin-tazobactam** | Excellent | β-lactam/β-lactamase inhibitor; covers *Pseudomonas*, anaerobes | | **Carbapenems (meropenem, imipenem)** | Excellent | Broad-spectrum; reserve for severe/resistant cases | | **Ceftazidime** | Good | 3rd-generation cephalosporin with antipseudomonal activity | | **Fluoroquinolones** | Poor in this case | Patient's isolate is fluoroquinolone-resistant; monotherapy inadequate | | **Ceftriaxone** | Inadequate | Does NOT cover *Pseudomonas* reliably | **Clinical Pearl:** VAP caused by *Pseudomonas* requires **dual antipseudomonal therapy** in severe cases (sepsis, high APACHE score). However, monotherapy with piperacillin-tazobactam or carbapenem is acceptable if the organism is susceptible and the patient is hemodynamically stable. **Warning:** Fluoroquinolone monotherapy is contraindicated here because: 1. The isolate is fluoroquinolone-resistant (documented in the stem) 2. Monotherapy with a resistant agent will lead to treatment failure and increased mortality 3. VAP requires broader, more potent agents ## Why Piperacillin-Tazobactam or Carbapenem? 1. **Antipseudomonal coverage:** Both agents reliably cover *P. aeruginosa* 2. **Anaerobic coverage:** Piperacillin-tazobactam also covers anaerobes (important post-operatively) 3. **Lung penetration:** Excellent intracellular and epithelial lining fluid concentrations 4. **Guideline-recommended:** IDSA VAP guidelines recommend these agents for MDR gram-negative VAP 5. **Susceptibility:** The organism is susceptible (no resistance documented to β-lactams) ## Glycemic Control **High-Yield:** Tight glycemic control (target 140–180 mg/dL in ICU) reduces VAP incidence and mortality. Insulin infusion is indicated for this patient's glucose of 280 mg/dL. [cite:Harrison 21e Ch 297]